HE4在上皮性卵巢癌中的表达情况及其与临床特征及预后的关系分析

目的 探讨HE4在上皮性卵巢癌中的表达情况及其与临床特征及预后的关系.方法 选取150例上皮性卵巢癌患者和72例良性卵巢疾病患者,采用酶联免疫吸附法(ELISA)检测并比较150例上皮性卵巢癌患者和72例良性卵巢疾病患者的血清HE4水平;采用免疫组织化学法(IHC)检测150例上皮性卵巢癌患者癌组织和相应癌旁正常组织中HE4的表达情况,分析其与上皮性卵巢癌临床特征的关系;随访36个月,记录并分析HE4表达与上皮性卵巢癌患者生存情况的关系.结果 上皮性卵巢癌患者的血清HE4水平明显高于良性卵巢疾病患者,上皮性卵巢癌组织中HE4蛋白的阳性表达率明显高于癌旁正常组织,差异均有统计学意义(P﹤0.01);肿瘤直径﹥3 cm、低分化、Ⅲ～Ⅳ期、有淋巴结转移的上皮性卵巢癌组织的HE4蛋白的阳性表达率分别高于肿瘤直径≤3 cm、中高分化、Ⅰ～Ⅱ期、无淋巴结转移的癌组织,差异均有统计学意义(P﹤0.05);随访36个月,HE4蛋白阳性表达的上皮性卵巢癌患者的生存率低于阴性表达的患者,差异有统计学意义(P﹤0.05).结论 HE4是上皮性卵巢癌的良好肿瘤标志物,与肿瘤的良、恶性鉴别及临床特征有密切的关系,对上皮性卵巢癌患者的早期诊断及预后有一定的价值.

The expression of HE4 in epithelial ovarian cancer and its correlation with clinical features and prognosis

Objective To explore the expression of HE4 in epithelial ovarian cancer and its correlation with clinical features and prognosis. Method 150 patients with epithelial ovarian cancer and 72 patients with benign ovarian diseases were included in the analysis. The expression levels of serum HE4 in all patients were detected by enzyme-linked immu-nosorbent assay (ELISA), and were then compared; immunohistochemistry (IHC) was used to detect the expression of HE4 in 150 cases of epithelial ovarian cancer and its adjacent normal tissues, and to analyze the correlation between the expression and clinical features of epithelial ovarian cancer;a follow-up visit (36 months) was conducted to record and analyze the relationship between HE4 and survival outcomes in patients with epithelial ovarian cancer. Result The level of serum HE4 of patients with epithelial ovarian cancer was obviously higher than that of patients with benign ovarian dis-eases;the positive rate of HE4 protein in epithelial ovarian cancer tissues was significantly higher than that in normal tis-sues (P<0.01);higher HE4 expression was observed in those with tumor diameter>3 cm, poor differentiation, stage III-IV disease, with lymph node metastasis, compared to those with tumor diameter≤3 cm, moderate-to-high differentiation, stage I-II disease, without lymph node metastasis, with statistically significant difference observed (P<0.05);after follow up for 36 months, the survival rate of epithelial ovarian cancer patients with positive HE4 was lower than that with nega-tive expression (P<0.05). Conclusion HE4 is a fairly good tumor marker of epithelial ovarian cancer, it is closely related to the differentiation of benign and malignant tumors and clinical manifestations, and it is clinically useful for early diag-nosis and prognosis.